Proteolysis in Alzheimer's disease. Can plasmin tip the balance?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

1. Pathological Defects in a Drosophila Model of Alzheimer's Disease and Beneficial Effects of the Natural Product Lisosan G.Biomolecules · 2024
   Article
2. Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis.International journal of molecular sciences · 2021
   Review
3. Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer's Disease.Molecular Medicine & Therapeutics · 2012
   Article
4. Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2011
   Article
5. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.Proceedings of the National Academy of Sciences of the United States of America · 2008
   Article
6. The TGF-beta1/upstream stimulatory factor-regulated PAI-1 gene: potential involvement and a therapeutic target in Alzheimer's disease.Journal of biomedicine & biotechnology · 2006
   Article
7. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2005
   Review

Corrections and comments

• Comment on
  Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.2000

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as